Edema as the most frequent tepotinib AE is a common class effect AE with MET inhibitors and has been reported with capmatinib (all cause peripheral edema: 59.8%), crizotinib (treatment-related edema composite event: 50.7%), and savolitinib (treatment-related peripheral edema: 54.0%; refs. 59, 76, 77). This evidence concerns the gene MET and Peripheral edema.